Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alisporivir - Debiopharm

Next Previous
X
Search
Drug Profile

Alisporivir - Debiopharm

Alternative Names: DEB-025; DEBIO-025; DEBIO-25

Latest Information Update: 29 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Debiopharm
  • Developer Debiopharm; Solid Biosciences
  • Class Ciclosporins
  • Mechanism of Action Cyclophilin inhibitors; HIV replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II COVID 2019 infections
  • Preclinical Gastrointestinal disorders
  • Discontinued Duchenne muscular dystrophy; Hepatitis C; HIV infections

Most Recent Events

  • 29 Nov 2022 Alisporivir is still in phase II trials for Covid-19 infections (In the elderly, In adults) in France (EudraCT2020-002295-13)
  • 13 Apr 2022 Debiopharm completes a phase II trial for Covid-19 infections (In the elderly, In adults) in France (NCT04608214) (EudraCT2020-002295-13)
  • 08 Jan 2021 Phase-II clinical trials in COVID-2019 infections (In adults, In the elderly) in France (PO) (EudraCT2020-002295-13)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top